Follow-up on patients treated for uveal melanoma with specialized radiation therapy
Longitudinal Follow-Up of Retinopathy and Opticopathy After Treatment With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma
Medical University of Vienna · NCT06280040
This study is testing how radiation treatment for uveal melanoma affects eye health over time by checking for eye problems in patients after their therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Vienna (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Vienna) |
| Trial ID | NCT06280040 on ClinicalTrials.gov |
What this trial studies
This study evaluates the incidence and severity of retinopathy and opticopathy in patients treated with hypofractionated stereotactic photon radiotherapy for uveal melanoma. Patients will undergo imaging assessments before treatment and at 3, 6, 9, and 12 months post-treatment using various ocular imaging techniques. The goal is to gather data on the long-term effects of this radiation therapy on eye health.
Who should consider this trial
Good fit: Ideal candidates are patients with newly diagnosed uveal melanoma who are scheduled to receive hypofractionated stereotactic photon radiotherapy.
Not a fit: Patients who are unwilling to participate or have severe media opacity may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve understanding of the side effects of radiation therapy on patients with uveal melanoma, leading to better management and treatment strategies.
How similar studies have performed: While there may be studies on radiation therapy for uveal melanoma, this specific observational approach focusing on long-term ocular effects is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with newly diagnosed uveal melanoma, who will be treated with hypofractionated stereotactic photon radiotherapy as part of clinical routine. Exclusion Criteria: * unwillingness to participate in the study * severe media opacity
Where this trial is running
Vienna
- Department of Ophthalmology and Optometry, Medical University Vienna — Vienna, Austria (RECRUITING)
Study contacts
- Principal investigator: Reinhard Told, MD, PhD — Department for Ophthalmology and Optometry, Medical University of Vienna
- Study coordinator: Judith Kreminger, MD
- Email: judith.kreminger@meduniwien.ac.at
- Phone: 0043 1 40400 48470
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Uveal Melanoma